• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

锑联合低剂量局部应用重组人粒细胞巨噬细胞集落刺激因子可促进皮肤利什曼病溃疡愈合:一项随机、双盲、安慰剂对照研究。

Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study.

作者信息

Santos Jussamara B, de Jesus Amélia Ribeiro, Machado Paulo R, Magalhães Andréa, Salgado Kátia, Carvalho Edgar M, Almeida Roque P

机构信息

Servico de Imunologia, Hospital Universitario Professor Edgard Santos, Universidade Federal da Bahia, Salvador, Bahia, Brazil.

出版信息

J Infect Dis. 2004 Nov 15;190(10):1793-6. doi: 10.1086/424848. Epub 2004 Oct 18.

DOI:10.1086/424848
PMID:15499535
Abstract

Cutaneous leishmaniasis (CL) requires 2-6 months to heal. In an effort to reduce this healing time, we studied topically applied granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to antimonial therapy. Ten patients received antimony plus topical GM-CSF, and 10 patients received antimony plus placebo (saline). GM-CSF was diluted for topical use and was applied 3 times weekly for 3 weeks (1-2 microg/cm2/lesion). The mean +/- SD healing time was 43 +/- 14 days in the GM-CSF group and was 104+/-79 days in the placebo group (P=.043). Ten (100%) of 10 patients in the GM-CSF group healed within 60 days, compared with 5 (50%) of 10 patients in the placebo group. Two of the patients in the placebo group required retreatment with antimony. In conclusion, topically applied GM-CSF is effective in the management of CL.

摘要

皮肤利什曼病(CL)需要2至6个月才能愈合。为了缩短愈合时间,我们研究了局部应用粒细胞巨噬细胞集落刺激因子(GM-CSF)作为锑剂治疗的辅助手段。10名患者接受了锑剂加局部GM-CSF治疗,10名患者接受了锑剂加安慰剂(生理盐水)治疗。GM-CSF经稀释后用于局部,每周应用3次,共3周(1-2微克/平方厘米/皮损)。GM-CSF组的平均愈合时间为43±14天,安慰剂组为104±79天(P = 0.043)。GM-CSF组10名患者中有10名(100%)在60天内愈合,而安慰剂组10名患者中只有5名(50%)。安慰剂组有2名患者需要再次接受锑剂治疗。总之,局部应用GM-CSF对CL的治疗有效。

相似文献

1
Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study.锑联合低剂量局部应用重组人粒细胞巨噬细胞集落刺激因子可促进皮肤利什曼病溃疡愈合:一项随机、双盲、安慰剂对照研究。
J Infect Dis. 2004 Nov 15;190(10):1793-6. doi: 10.1086/424848. Epub 2004 Oct 18.
2
Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous Leishmaniasis.葡萄糖酸锑钠联合人粒细胞巨噬细胞集落刺激因子与单用葡萄糖酸锑钠治疗皮肤利什曼病的随机双盲研究
J Infect Dis. 1999 Nov;180(5):1735-7. doi: 10.1086/315082.
3
Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials.用粒细胞巨噬细胞集落刺激因子和抗锑剂成功治疗难治性皮肤利什曼病。
Am J Trop Med Hyg. 2005 Jul;73(1):79-81.
4
A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.标准剂量或低剂量的葡甲胺锑酸盐全身治疗联合口服奥美拉唑治疗皮肤利什曼病的疗效比较研究。
J Vector Borne Dis. 2008 Dec;45(4):287-91.
5
A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.一项随机试验,比较粒细胞-巨噬细胞集落刺激因子加粒细胞集落刺激因子联合应用与粒细胞集落刺激因子用于动员造血祖细胞产品中树突状细胞亚群的效果。
Biol Blood Marrow Transplant. 2004 Dec;10(12):848-57. doi: 10.1016/j.bbmt.2004.07.008.
6
A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil.巴西一项评估米替福新与局部粒细胞巨噬细胞集落刺激因子治疗巴西利什曼原虫引起的皮肤利什曼病的双盲、随机试验。
Clin Infect Dis. 2021 Oct 5;73(7):e2465-e2469. doi: 10.1093/cid/ciaa1337.
7
Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis.全身性葡糖胺锑钠与己酮可可碱联合治疗皮肤利什曼病的疗效
Int J Dermatol. 2006 Jul;45(7):819-21. doi: 10.1111/j.1365-4632.2006.02867.x.
8
START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease.START试验:一项关于使用皮下注射粒细胞巨噬细胞集落刺激因子刺激动脉生成作为外周血管疾病新疗法的试点研究。
Circulation. 2005 Aug 16;112(7):1040-6. doi: 10.1161/CIRCULATIONAHA.104.529552. Epub 2005 Aug 8.
9
A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis.
J Vector Borne Dis. 2006 Dec;43(4):161-7.
10
[Effect of recombinant human granulocyte-macrophage colony stimulating factor on wound healing in patients with deep partial thickness burn].[重组人粒细胞巨噬细胞集落刺激因子对深Ⅱ度烧伤患者创面愈合的影响]
Zhonghua Shao Shang Za Zhi. 2008 Apr;24(2):107-10.

引用本文的文献

1
Contribution of epidermal growth factor (EGF) in the treatment of cutaneous leishmaniasis caused by Leishmania major in BALB/c mice.表皮生长因子(EGF)在治疗BALB/c小鼠体内由硕大利什曼原虫引起的皮肤利什曼病中的作用。
PLoS Negl Trop Dis. 2025 Jan 14;19(1):e0012765. doi: 10.1371/journal.pntd.0012765. eCollection 2025 Jan.
2
Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis.免疫治疗策略作为皮肤利什曼病的潜在治疗选择
Vaccines (Basel). 2024 Oct 17;12(10):1179. doi: 10.3390/vaccines12101179.
3
Pentavalent Antimony Associated with G-CSF in the Treatment of Cutaneous Leishmaniasis Caused by .
五价锑与粒细胞集落刺激因子联合用于治疗由……引起的皮肤利什曼病
Pathogens. 2024 Apr 4;13(4):301. doi: 10.3390/pathogens13040301.
4
Therapeutic effect of oral quercetin in hamsters infected with .口服槲皮素对感染 的仓鼠的治疗效果。
Front Cell Infect Microbiol. 2023 Jan 13;12:1059168. doi: 10.3389/fcimb.2022.1059168. eCollection 2022.
5
A Mouse Model of Ulcerative Cutaneous Leishmaniasis by to Investigate Infection, Pathogenesis, Immunity, and Therapeutics.一种用于研究感染、发病机制、免疫和治疗方法的溃疡性皮肤利什曼病小鼠模型。
Front Microbiol. 2022 Jun 13;13:907631. doi: 10.3389/fmicb.2022.907631. eCollection 2022.
6
Protection and Pathology in Infection.感染中的保护与病理学
Pathogens. 2022 Apr 14;11(4):466. doi: 10.3390/pathogens11040466.
7
Host-Directed Therapies for Cutaneous Leishmaniasis.针对皮肤利什曼病的宿主导向疗法。
Front Immunol. 2021 Mar 26;12:660183. doi: 10.3389/fimmu.2021.660183. eCollection 2021.
8
The transition of M-CSF-derived human macrophages to a growth-promoting phenotype.M-CSF 诱导的人巨噬细胞向促生长表型的转化。
Blood Adv. 2020 Nov 10;4(21):5460-5472. doi: 10.1182/bloodadvances.2020002683.
9
A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil.巴西一项评估米替福新与局部粒细胞巨噬细胞集落刺激因子治疗巴西利什曼原虫引起的皮肤利什曼病的双盲、随机试验。
Clin Infect Dis. 2021 Oct 5;73(7):e2465-e2469. doi: 10.1093/cid/ciaa1337.
10
Interventions for American cutaneous and mucocutaneous leishmaniasis.美国皮肤利什曼病和黏膜皮肤利什曼病的干预措施。
Cochrane Database Syst Rev. 2020 Aug 27;8(8):CD004834. doi: 10.1002/14651858.CD004834.pub3.